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Abstract
A 34-week infant born from a mother with a history of drug abuse developed neonatal absti-
nence syndrome (NAS) in the ﬁrst hours of life. Urine drug screening was positive for cocaine and
heroin. The infant developed acute kidney injury and bilateral hydronephrosis while receiving oral
morphine for control of NAS. Cessation of morphine therapy and urinary catheterization resulted
in a rapid and complete resolution of the symptoms. Our patient was homozygous for the
C3435T polymorphism in the ABCB1 gene, a polymorphism previously associated with impaired
P-glycoprotein activity. We hypothesize that acute renal toxicity was related to accumulation of
morphine within urothelial cells due to genetically determined impaired P-glycoprotein activity.
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Introduction
Morphine is frequently used to relieve pain and achieve
sedation in many age groups. In preterm infants, mor-
phine is largely used for pain control in neonatal intensive
care units and for the management of the neonatal absti-
nence syndrome (NAS). Despite its recognized beneﬁts,
the use of morphine is associated with adverse effects on
the cardiovascular, gastrointestinal and nervous systems
such as hypotension, bradycardia, seizures, decreased
gastrointestinal motility, intestinal obstruction and respir-
atory depression [1, 2]. Renal side effects of morphine
(urethral spasm, spasm of bladder sphincters, urinary re-
tention or hesitancy, antidiuretic effect and rhabdomyoly-
sis) have been previously reported in adult patients [3, 4].
Little is however known about the adverse kidney effects
of morphine on paediatric patients and, in particular, in
preterm infants [1, 2, 5, 6].
Studies in adults indicate that peripheral mechanisms
may play a role in opioid-induced bladder dysfunction and
urinary retention [7, 8]. However, the exact mechanism by
which morphine causes urinary retention and renal im-
pairment in premature infants is unknown. Age-related
difference in morphine clearance may contribute to the
observed different response to opioid therapy from infancy
to adulthood [9–11]. Additionally, the pharmacokinetics
and pharmacodynamics of morphine are inﬂuenced by
several polymorphic genes [12]. Preliminary data suggest
that variation in genes coding the drug-metabolizing
enzyme (UGT2B7), mu-opioid receptors (OPRM1), the
enzyme degrading catecholamines (COMT) and intracellu-
lar drug accumulation by P-glycoprotein (ABCB1) can sig-
niﬁcantly inﬂuence the clinical outcome of patients given
morphine therapy [13–16]. Despite this, the pharmacoge-
netics of morphine have not been previously considered
in the paediatric population as an explanation for poor
drug response and/or for drug side effects.
We report a case of acute kidney injury and bilateral
hydronephrosis in a premature infant homozygous for the
C3435T polymorphism in the ABCB1 gene treated with oral
morphine. We believe that this is the ﬁrst published report
demonstrating a relationship between renal morphine
toxicity and genetic background in paediatric patients.
Case report
A 2240 g Caucasian male neonate was born at 34 weeks
of gestation by emergency caesarean section performed
for premature rupture of membrane. The mother was
HIV-positive and had a history of cocaine and heroin
abuse throughout her pregnancy. Apgar scores at 1 and
5 min after birth were 6 and 8, respectively. One hour
after birth, the infant developed an NAS characterized by
central nervous system irritability, tremors, poor feeding,
exaggerated Moro reﬂex, increased muscle tone and
uncoordinated sucking. His Finnegan Score (which com-
prehensively scores all relevant clinical signs of NAS in
newborn infants during the ﬁrst days of life assessing
central nervous system hyperirritability, gastrointestinal
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dysfunction, respiratory distress and vague autonomic
signs in a semi-quantitative way [17]) yielded a result of
>12 (a Finnegan score of 8 or higher is considered severe
and requires medical therapy).
A urine test performed soon after birth was positive for
cocaine and heroin. Treatment with oral morphine was
immediately started (0.5 mg/kg/24 h in four divided
doses given every 6 h and then decreased to 0.4 mg/kg/
24 h in three divided doses given every 8 h). To reduce
the risk of vertical HIV transmission, oral zidovudine was
started at 6 h of life. On Day 5, urine output decreased
gradually and the serum creatinine level increased from
77.8 to 93.7 μmol/L (from 0.88 to 1.06 mg/dL) on Day 7
(Table 1). The potassium level rose concomitantly from
4.1 to 6.2 mmol/L (from 4.1 to 6.2 meq/L), whereas
sodium remained normal without the development of
metabolic acidosis. Physical examination revealed hypo-
tonia, lethargy, distended abdomen and a vesical globe.
A renal ultrasound showed bladder distension with bilat-
eral hydronephrotic kidneys [bipolar length 4.5 cm
(normal for age 3–4 cm)]. Urinary catheterization drained
73 mL of straw-coloured urine with resolution of the
bladder distension. Morphine was discontinued without
rebound or adverse effects and over the subsequent 3
days, renal function returned to normal (Table 1). Repeat
ultrasound conﬁrmed the resolution of hydronephrosis.
An additional blood sample was collected for phar-
macogenetic analyses (after informed consent was
obtained from the mother). According to pyrosequen-
cing analysis, the patient was wild type for the most
common allelic variants of UGT2B7, OPRM1 and COMT
genes. However, he was homozygous for the C3435T
(rs1045642) polymorphism of the ABCB1 gene that
has been previously associated with absent/impaired
P-glycoprotein activity [18].
The infant was discharged on Day 33: no further
urinary retention was observed during hospitalization.
Oral zidovudine therapy was continued for 6 weeks after
birth and was well tolerated. The infant was followed
during the ﬁrst 18 months of life to monitor growth and
renal development: no sign of renal impairment was
reported and the transmission of HIV infection was
excluded.
Discussion
A few cases of acute kidney injury and hydronephrosis
have been reported in the literature after opioid adminis-
tration in preterm infants [5, 6]. To our knowledge, this is
the ﬁrst case in which a possible pharmacogenetic cause
has been identiﬁed. Other important causes of acute
kidney injury bladder distension and hydronephrosis,
such as urological malformations, neoplasia, vesicouret-
eral reﬂux and neurogenic bladder, were excluded in this
case. The renal impairment was also reversible and
improved soon after discontinuation of morphine. The
clinical evidence thus suggests a pathophysiological
mechanism related to morphine. Nevertheless, the possi-
bility that other as yet unknown factors may be involved
cannot be excluded.
Our patient was homozygous for a polymorphic variant
in position 3435 of the ABCB1 gene. This gene encodes for
P-glycoprotein, a protein that belongs to the ABC transpor-
ter family and is expressed in leucocytes, hepatocytes,
blood–brain barrier and mainly on the brush border of
enterocytes and renal tubular cells [18]. Importantly,
P-glycoprotein is also expressed in urothelial cells [19–22],
playing a key role in the disposition of chemotherapy in ur-
othelial cancers [19, 21]. Our patient experienced acute
kidney injury and bilateral hydronephrosis while receiving
oral morphine for the control of NAS. This resolved after
urinary catheterization, suggesting that the site of the ob-
struction was the bladder neck. We hypothesize that acute
renal toxicity was related to accumulation of morphine
and its metabolite within urothelial cells due to genetically
determined, impaired P-glycoprotein activity.
A potential limitation is that we did not measure the
plasma concentrations of morphine and its main glucuro-
nide metabolite. However, studies showing the impact of
C3435T polymorphism in the ABCB1 gene on clinical out-
comes have consistently failed to demonstrate an associ-
ation with blood drug concentrations, suggesting a local
(rather than systemic) effect on drug disposition [15, 23].
P-glycoprotein is an efﬂux transporter that actively trans-
ports lipophilic drugs from the intracellular to the extra-
cellular domain. Consequently, reduced expression and/
or altered activity of P-glycoprotein can increase the
intracellular and tissue drug concentrations, ultimately
resulting in local drug toxicity.
Studies aimed at investigating the role of ABCB1 poly-
morphisms on morphine efﬁcacy and/or safety have
provided conﬂicting results. Some studies have reported
signiﬁcant associations between allelic T variants of
ABCB1 with morphine-induced adverse gastrointestinal
and central drug reactions in adults patients with cancer
[14, 15], whereas other investigators have failed to docu-
ment a role of genetic factors with morphine response
[24–26]. No clinical studies have previously addressed
the role of ABCB1 polymorphisms on morphine-related
Table 1. Time course of the main biochemical and clinical parameters observed in our patient
Parameters Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10
At
discharge
Normal
values
S. creatinine
(μmol/L)
77.8 — 85.7 — — 82.2 93.7 79.6 71.6 — 46.9 50–100
Urine output
(mL/kg/h)
Wet
diapera
Wet
diapera
Wet
diapera
∼3 ∼2.0 3.0 b 2.7 3.0 2.5 4.0 >1–2
S. potassium
(mmol/L)
3.9 4.0 3.5 3.9 4.1 5.3 6.2 4.6 4.2 4.6 4.1 3.5–5.0
Morphine dose
(mg/kg/24 h)
0.5 0.7 0.6 0.4 0.4 0.3 Interrupted — — — —
Finnegan’s
score
12 11 4 6 6 5 4 8 4 4 2 <8
aThe patient was not catheterized and no quantitative assessment was performed.
bUrinary catheterization performed, residual volume 73 mL.
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kidney injury and our single case report does not provide
a deﬁnitive conclusion on this topic. Nevertheless, we
believe that it provides an intriguing mechanistic hypoth-
esis that needs further investigation.
Conclusion
Pain and NAS in newborns are therapeutically managed
by the administration of opioids. Morphine is one of the
most important and widely used opioids in neonatology;
but, large variability in its efﬁcacy and/or safety rep-
resents a major clinical challenge. Clinical pharmacology
studies in adults have demonstrated the importance of
pharmacogenetics in determining the response to drug
therapy [27–29]. Our observation is in line with these
data and suggests that pharmacogenetics can aid our
understanding of morphine-induced adverse effects in
neonates as in other age groups.
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